Paul Matteis
Stock Analyst at Stifel
(2.05)
# 3,018
Out of 4,964 analysts
109
Total ratings
41.67%
Success rate
-6.51%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $392.05 | +16.06% | 19 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $138.94 | +25.23% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $13.75 | +161.82% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $104.23 | -9.81% | 2 | May 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $452.33 | -23.73% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.76 | +13.64% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $25.77 | +24.18% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $13.84 | +131.21% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $4.81 | +128.69% | 1 | Feb 27, 2025 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $16.26 | +96.80% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.39 | +67.36% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.81 | +162.47% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $18.80 | +219.15% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.93 | +24.44% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $57.68 | +50.83% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.80 | +108.33% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $42.62 | +24.35% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $26.23 | -19.94% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $10.12 | +186.56% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $132.65 | +116.36% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.76 | +320.17% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.23 | +271.52% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.20 | +1,900.00% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.40 | +1,164.22% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $13.51 | +136.86% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.31 | +1,961.07% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $14.62 | -4.24% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $9.93 | +544.51% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $65.23 | +421.23% | 1 | Dec 21, 2016 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $392.05
Upside: +16.06%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $138.94
Upside: +25.23%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $13.75
Upside: +161.82%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $104.23
Upside: -9.81%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $452.33
Upside: -23.73%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.76
Upside: +13.64%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $25.77
Upside: +24.18%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $13.84
Upside: +131.21%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $4.81
Upside: +128.69%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $16.26
Upside: +96.80%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.39
Upside: +67.36%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.81
Upside: +162.47%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $18.80
Upside: +219.15%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.93
Upside: +24.44%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $57.68
Upside: +50.83%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $16.80
Upside: +108.33%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $42.62
Upside: +24.35%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $26.23
Upside: -19.94%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $10.12
Upside: +186.56%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $132.65
Upside: +116.36%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $4.76
Upside: +320.17%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $3.23
Upside: +271.52%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.20
Upside: +1,900.00%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.40
Upside: +1,164.22%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $13.51
Upside: +136.86%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.31
Upside: +1,961.07%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $14.62
Upside: -4.24%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $9.93
Upside: +544.51%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $65.23
Upside: +421.23%